Industry
Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 9:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 11:03 am
Portfolio Pulse from Benzinga Insights
June 05, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 9:24 pm
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 2:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 25, 2024 | 9:56 pm
Portfolio Pulse from Benzinga Newsdesk
January 22, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Insights
December 29, 2023 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.